Obesity is associated with lower levels of 25-hydroxyvitamin D [25(OH)D] and higher cardiovascular risk related to metabolic syndrome (MetS). Our purpose was to investigate if there is an association between levels of 25(OH)D and the components of MetS in an obese sample.
Methods:
This cross-sectional study enrolled obese patients referred for bariatric surgery in a specialized clinic. Secondary data were gathered as follows: glycemic and lipid profiles, 25(OH)D, anthropometric parameters, and clinical and sociodemographic information. The results were presented as means (standard deviations) or medians and interquartile intervals or absolute and relative frequencies. The patients were divided into three groups based on 25(OH)D terciles for analysis and were compared using ANOVA, Kruskal–Wallis or chi-squared tests. The correlations were calculated by Spearman's or Pearson's correlation tests.
Results:
We studied 299 patients, with the majority being women (74.9%). The patients' average (SD) age and 25(OH)D level were 36 (9) years and 25.8 (7.5) ng/mL, respectively. There was no association between vitamin D and MetS or its components. A progressive decrease in total cholesterol, low-density lipoprotein cholesterol (LDL-c), and nonhigh-density lipoprotein cholesterol (HDL-c) was observed as the serum vitamin D level increased, although only the latter reached statistical significance (P = 0.033). The correlation analysis showed a negative linear association between 25(OH)D and total cholesterol (r = −0.157; P = 0.047), 25(OH)D and LDL-c (r = −0.164; P = 0.038), and 25(OH)D and non-HDL-c (r = −0.176; P = 0.026).
Conclusions:
There was a negative correlation between 25(OH)D levels and the atherogenic profile but none with the MetS.
Get full access to this article
View all access options for this article.
References
1.
Hossein-nezhadA, SpiraA, HolickMF. Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: A randomized double-blind clinical trial. PLoS One, 2013; 8:e58725.
2.
SchuchNJ, GarciaVC, VívoloSRGF, et al.Relationship between Vitamin D Receptor gene polymorphisms and the components of metabolic syndrome. Nutr J, 2013; 12:96.
3.
Ruiz-OjedaFJ, Anguita-RuizA, LeisR, et al.Genetic factors and molecular mechanisms of vitamin D and obesity relationship. Ann Nutr Metab, 2018; 73:89–99.
4.
HannemannA, ThuesenBH, FriedrichN, et al.Adiposity measures and vitamin D concentrations in Northeast Germany and Denmark. Nutr Metab, 2015; 12:24.
5.
BelliaA, GarcovichC, D'AdamoM, et al.Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Intern Emerg Med, 2013; 8:33–40.
6.
JungUJ, ChoiM-S. Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci, 2014; 15:6184–6223.
7.
MaedaSS, BorbaVZC, CamargoMBR, et al.Recommendations of the Brazilian Society of Endocrinology and Metabology (SBEM) for the diagnosis and treatment of hypovitaminosis D. Arq Bras Endocrinol Metabol, 2014; 58:411–433.
8.
BilgeU, ÜnalacakM, ÜnlüogluI, et al.Relationship between 1,25-dihydroxy Vitamin D levels and homeostatic model assessment insulin resistance values in obese subjects. Niger J Clin Pract, 2015; 18:377–380.
9.
FaludiAA, IzarMco, SaraivaJFK, et al.Atualização Da Diretriz Brasileira De Dislipidemias E Prevenção Da Aterosclerose—2017 [Actualization of Brazilian Guideline for Dyslipidemia and Prevention of Atherosclerosis]. Arq Bras Cardiol. 2017 Jul;109(2 Supl 1):1–76. DOI: 10.5935/abc.20170121
10.
Pi-SunyerF. National Institute of Health (NIH). National Heart, Lung and Blood Insitute (NHLBI). The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. 2000. Available on https://www.nhlbi.nih.gov/files/docs/guidelines/prctgd_c.pdf
11.
AlbertiKGMM, EckelRH, GrundySM, et al.Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009; 120:1640–1645.
12.
CotrimHP, PariseER, Figueiredo-MendesC, et al.Nonalcoholic fatty liver disease Brazilian Society of Hepatology Consensus. Arq Gastroenterol, 2016; 53:118–122.
13.
AshwellM, GibsonS. Waist-to-height ratio as an indicator of “early health risk”: Simpler and more predictive than using a “matrix” based on BMI and waist circumference. BMJ Open, 2016; 6:e010159.
14.
Clemente-PostigoM, Muñoz-GarachA, SerranoM, et al.Serum 25-hydroxyvitamin D and adipose tissue vitamin D receptor gene expression: Relationship with obesity and type 2 diabetes. J Clin Endocrinol Metab, 2015; 100:E591–E595.
15.
FaridiKF, ZhaoD, MartinSS, et al.Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study. Nutr Burbank Los Angel Cty Calif, 2017; 38:85–93.
16.
KhanRJ, GebreabSY, RiestraP, et al.Associations between vitamin D and cardiovascular disease risk factors in African Americans are partly explained by circulating adipokines and C-reactive protein: The Jackson Heart Study. J Nutr, 2016; 146:2537–2543.
17.
Pereira-SantosM, CostaPRF, AssisAMO, et al.Obesity and vitamin D deficiency: A systematic review and meta-analysis. Obes Rev Off J Int Assoc Study Obes, 2015; 16:341–349.
18.
MirhosseiniN, RainsburyJ, KimballSM. Vitamin D supplementation, serum 25(OH)D concentrations and cardiovascular disease risk factors: A systematic review and meta-analysis. Front Cardiovasc Med, 2018; 5:87.
19.
GlueckCJ, JettyV, RothschildM, et al.Associations between serum 25-hydroxyvitamin D and lipids, lipoprotein cholesterols, and homocysteine. North Am J Med Sci, 2016; 8:284–290.
20.
PolidoroL, ProperziG, MaramponF, et al.Vitamin D protects human endothelial cells from H2O2 oxidant injury through the Mek/Erk-Sirt1 axis activation. J Cardiovasc Transl Res, 2013; 6:221–231.
21.
SentinelliF, BertocciniL, BarchettaI, et al.The vitamin D receptor (VDR) gene rs11568820 variant is associated with type 2 diabetes and impaired insulin secretion in Italian adult subjects, and associates with increased cardio-metabolic risk in children. Nutr Metab Cardiovasc Dis NMCD, 2016; 26:407–413.
22.
Al-DaghriNM, AlkharfyKM, Al-SalehY, et al.Modest reversal of metabolic syndrome manifestations with vitamin D status correction: A 12-month prospective study. Metabolism, 2012; 61:661–666.
23.
van de LuijtgaardenKM, VoûteMT, HoeksSE, et al.Vitamin D deficiency may be an independent risk factor for arterial disease. Eur J Vasc Endovasc Surg, 2012; 44:301–306.
24.
EsteghamatiA, AryanZ, EsteghamatiA, et al.Differences in vitamin D concentration between metabolically healthy and unhealthy obese adults: Associations with inflammatory and cardiometabolic markers in 4391 subjects. Diabetes Metab, 2014; 40:347–355.
25.
Obispo EntrenasA, Legupin TubioD, Lucena NavarroF, et al.Relationship between vitamin D deficiency and the components of metabolic syndrome in patients with morbid obesity, before and 1 year after laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy. Obes Surg, 2017; 27:1222–1228.
26.
BonakdaranS, FakhraeeF, KarimianMS, et al.Association between serum 25-hydroxyvitamin D concentrations and prevalence of metabolic syndrome. Adv Med Sci, 2016; 61:219–223.
27.
Boonchaya-anantP, HolickMF, ApovianCM. Serum 25-hydroxyvitamin D levels and metabolic health status in extremely obese individuals. Obes Silver Spring Md, 2014; 22:2539–2543.
28.
MiñambresI, Sánchez-HernándezJ, Sánchez-QuesadaJL, et al.The association of hypovitaminosis d with the metabolic syndrome is independent of the degree of obesity. ISRN Endocrinol, 2012; 2012:691803.
29.
Al-KhalidiB, KimballSM, KukJL, et al.Metabolically healthy obesity, vitamin D, and all-cause and cardiometabolic mortality risk in NHANES III. Clin Nutr Edinb Scotl, 2019; 38:820–828.
30.
HjelmesaethJ, Hofsø D, Aasheim ET, et al. Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: A cross-sectional study. Cardiovasc Diabetol, 2009; 8:7.
31.
VogtS, BaumertJ, PetersA, ThorandB, et al.Effect of waist circumference on the association between serum 25-hydroxyvitamin D and serum lipids: Results from the National Health and Nutrition Examination Survey 2001–2006. Public Health Nutr, 2017; 20:1797–1806.
32.
VilarrasaN, VendrellJ, MaravallJ, et al.Is plasma 25(OH) D related to adipokines, inflammatory cytokines and insulin resistance in both a healthy and morbidly obese population?. Endocrine, 2010; 38:235–242.
33.
SalekzamaniS, MehralizadehH, GhezelA, et al.Effect of high-dose vitamin D supplementation on cardiometabolic risk factors in subjects with metabolic syndrome: A randomized controlled double-blind clinical trial. J Endocrinol Invest, 2016; 39:1303–1313.
34.
MousaA, NaderpoorN, de CourtenMPJ, et al.25-hydroxyvitamin D is associated with adiposity and cardiometabolic risk factors in a predominantly vitamin D-deficient and overweight/obese but otherwise healthy cohort. J Steroid Biochem Mol Biol, 2017; 173:258–264.
35.
HolickMF, BinkleyNC, Bischoff-FerrariHA, et al.Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2011; 96:1911–1930.
36.
MunnsCF, ShawN, KielyM, et al.Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. J Clin Endocrinol Metab, 2016; 101:394–415.
